About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2013 (2013), Article ID 365723, 12 pages
http://dx.doi.org/10.1155/2013/365723
Research Article

Rapid Screening of Novel Agents for Combination Therapy in Sarcomas

1Chemical Biology and Molecular Medicine, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
2Translational Research Lab, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
3Small Animal Imaging Lab, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
4Sarcoma Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
5Anatomic Pathology Department, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA

Received 6 June 2013; Revised 4 September 2013; Accepted 5 September 2013

Academic Editor: Chandrajit Premanand Raut

Copyright © 2013 Christopher L. Cubitt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Reed and S. Altiok, “Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine,” Cancer Control, vol. 18, no. 3, pp. 188–195, 2011. View at Scopus
  2. C. D. Blanke, C. Rankin, G. D. Demetri et al., “Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 626–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Van Glabbeke, J. Verweij, I. Judson, and O. S. Nielsen, “Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas,” European Journal of Cancer, vol. 38, no. 4, pp. 543–549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Tariq Mahmood, S. Agresta, C. E. Vigil et al., “Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma,” International Journal of Cancer, vol. 129, no. 8, pp. 1963–1969, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. T.-C. Chou and P. Talalay, “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors,” Advances in Enzyme Regulation, vol. 22, pp. 27–55, 1984. View at Scopus
  6. D. Siegel, M. Hussein, C. Belani et al., “Vorinostat in solid and hematologic malignancies,” Journal of Hematology and Oncology, vol. 2, article 31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Fouladi, J. R. Park, C. F. Stewart et al., “Pediatric phase I trial and pharmacokinetic study of vorinostat: a children's oncology group phase I consortium report,” Journal of Clinical Oncology, vol. 28, no. 22, pp. 3623–3629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, “Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3129–3140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. L. J. Lombardo, F. Y. Lee, P. Chen et al., “Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays,” Journal of Medicinal Chemistry, vol. 47, no. 27, pp. 6658–6661, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. O. Hantschel, U. Rix, and G. Superti-Furga, “Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib,” Leukemia and Lymphoma, vol. 49, no. 4, pp. 615–619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Olivieri and L. Manzione, “Dasatinib: a new step in molecular target therapy,” Annals of Oncology, vol. 18, no. 6, pp. vi42–vi46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Berndt, H. Yang, B. Trinczek et al., “The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane,” Cell Death and Differentiation, vol. 17, no. 11, pp. 1795–1804, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. R. Garrett, D. Coppola, R. M. Wenham et al., “Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT,” Investigational new drugs, vol. 29, no. 6, pp. 1381–1389, 2011. View at Scopus
  14. T. A. Yap, L. Yan, A. Patnaik et al., “First-in-man clinical trial of the oral pan-AKT inhibitor MK-206 in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 29, no. 35, pp. 4688–4695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Neale, X. Su, C. L. Morton et al., “Molecular characterization of the pediatric preclinical testing panel,” Clinical Cancer Research, vol. 14, no. 14, pp. 4572–4583, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. J. Houghton, C. L. Morton, C. Tucker et al., “The pediatric preclinical testing program: description of models and early testing results,” Pediatric Blood & Cancer, vol. 49, no. 7, pp. 928–940, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Gorlick, J. M. Maris, P. J. Houghton, et al., “Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program,” Pediatric Blood & Cancer, vol. 59, no. 3, pp. 518–524, 2012. View at Publisher · View at Google Scholar
  18. S. T. Keir, J. M. Maris, R. Lock et al., “Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program,” Pediatric Blood & Cancer, vol. 55, no. 6, pp. 1126–1133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Carol, P. J. Houghton, C. L. Morton et al., “Initial testing of topotecan by the pediatric preclinical testing program,” Pediatric Blood & Cancer, vol. 54, no. 5, pp. 707–715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Keshelava, P. J. Houghton, C. L. Morton et al., “Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program,” Pediatric Blood & Cancer, vol. 53, no. 3, pp. 505–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. E. A. Kolb, R. Gorlick, P. J. Houghton et al., “Initial testing of dasatinib by the pediatric preclinical testing program,” Pediatric Blood & Cancer, vol. 50, no. 6, pp. 1198–1206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. P. J. Houghton, C. L. Morton, R. Gorlick et al., “Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program,” Molecular Cancer Therapeutics, vol. 9, no. 1, pp. 101–112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Aplenc and C. Ahern, “Study ADVL0516 Progress Report,” Study Committee Progress Report—Children's Oncology Group, August 2009.
  24. M. Fouladi, W. L. Furman, T. Chin et al., “Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a children's oncology group report,” Journal of Clinical Oncology, vol. 24, no. 22, pp. 3678–3685, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Knipstein and L. Gore, “Entinostat for treatment of solid tumors and hematologic malignancies,” Expert Opinion on Investigational Drugs, vol. 20, no. 10, pp. 1455–1467, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Cortes, P. Rousselot, D.-W. Kim et al., “Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis,” Blood, vol. 109, no. 8, pp. 3207–3213, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. R. G. Maki, J. K. Wathen, S. R. Patel et al., “Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2755–2763, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Aplenc, S. M. Blaney, L. C. Strauss et al., “Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 839–844, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Choy, F. Hornicek, L. Macconaill et al., “High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes,” Cancer, vol. 118, no. 11, pp. 2905–2914, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Hernando, E. Charytonowicz, M. E. Dudas et al., “The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas,” Nature Medicine, vol. 13, no. 6, pp. 748–753, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Vivanco and C. L. Sawyers, “The phosphatidylinositol 3-kinase-AKT pathway in human cancer,” Nature Reviews Cancer, vol. 2, no. 7, pp. 489–501, 2002. View at Scopus
  32. Y. Tomita, T. Morooka, Y. Hoshida et al., “Reassessment of the 1993 Osaka grading system for localized soft tissue sarcoma in Japan,” Anticancer Research, vol. 26, no. 6C, pp. 4665–4669, 2006. View at Scopus
  33. R. Nitschke, J. Parkhurst, J. Sullivan, M. B. Harris, M. Bernstein, and C. Pratt, “Topotecan in pediatric patients with recurrent and progressive solid tumors: a pediatric oncology group phase II study,” Journal of Pediatric Hematology/Oncology, vol. 20, no. 4, pp. 315–318, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Hijiya, C. F. Stewart, Y. Zhou et al., “Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse,” Cancer, vol. 112, no. 9, pp. 1983–1991, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. L. Metzger, C. F. Stewart, B. B. Freeman III et al., “Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study,” Journal of Clinical Oncology, vol. 25, no. 21, pp. 3130–3136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Shamash, T. Powles, K. Mutsvangwa et al., “A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours,” Annals of Oncology, vol. 18, no. 5, pp. 925–930, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. N. C. Daw, V. M. Santana, L. C. Iacono et al., “Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 829–837, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. D. O. Walterhouse, E. R. Lyden, P. P. Breitfeld, S. J. Qualman, M. D. Wharam, and W. H. Meyer, “Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a children's oncology group study,” Journal of Clinical Oncology, vol. 22, no. 8, pp. 1398–1403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Garaventa, R. Luksch, S. Biasotti et al., “A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma,” Cancer, vol. 98, no. 11, pp. 2488–2494, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Kramer, B. H. Kushner, and N.-K. V. Cheung, “Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis,” Journal of Pediatric Hematology/Oncology, vol. 25, no. 8, pp. 601–605, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. W. L. Furman, C. F. Stewart, M. Kirstein et al., “Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a Pediatric Oncology Group study,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1617–1624, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Rubie, B. Geoerger, D. Frappaz et al., “Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours,” European Journal of Cancer, vol. 46, no. 15, pp. 2763–2770, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Rodriguez-Galindo, K. R. Crews, C. F. Stewart et al., “Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors,” Cancer Chemotherapy and Pharmacology, vol. 57, no. 1, pp. 15–24, 2006. View at Scopus
  44. W. T. van der Graaf, J. Y. Blay, S. P. Chawla, et al., “Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial,” The Lancet, vol. 379, no. 9829, pp. 1879–1886, 2012. View at Publisher · View at Google Scholar
  45. S. Kumar, R. B. Mokhtari, R. Sheikh et al., “Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor,” Clinical Cancer Research, vol. 17, no. 17, pp. 5656–5667, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Talpaz, N. P. Shah, H. Kantarjian et al., “Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias,” The New England Journal of Medicine, vol. 354, no. 24, pp. 2531–2541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. M. A. Smith and P. Houghton, “A proposal regarding reporting of in vitro testing results,” Clinical Cancer Research, vol. 19, no. 11, pp. 2828–2833, 2013. View at Publisher · View at Google Scholar
  48. M. Gerlinger, A. J. Rowan, S. Horswell et al., “Intratumor heterogeneity and branched evolution revealed by multiregion sequencing,” The New England Journal of Medicine, vol. 366, no. 10, pp. 883–892, 2012. View at Publisher · View at Google Scholar · View at Scopus